Bladder scanning before uroflowmetry is a useful test for reducing the amount of nonevaluable flow rate data. If a voided volume of greater than 125 mL (>150 mL) is required, the mandatory prevoiding bladder scan volume should be greater than 200 mL (>250 mL), which would decrease the number of noneligible flow rate recordings from 23.9% to 4.5% (31.3% to 4.5%).
From April 1989 to April 1994 we performed a mass-screening for early diagnosis of prostatic carcinoma (by D.R.E.) on 7303 men aged 50-79 years. Moreover we evaluated the prevalence of obstructive urinary symptoms and clinically significant B.P.H. We found a prevalence rate of benign prostatic hyperplasia of 17.3% (1259/7303). The most commonly found were incomplete bladder emptying, dribbling and weak stream force. The prevalence of urinary symptoms rose significantly with increasing age and prostate size (evaluated also by T.R.U.S. on 480 men). We haven't found clear correlations between BPH and occupational or environmental risk factors. Despite the good knowledge about the development of pathological B.P.H., there is little agreement about the definition of the clinical patterns of the disease. For Garraway, B.P.H. is an enlargement of the prostate gland for an equivalent weight >20 g. in the presence of symptoms of urinary dysfunction and/or a urinary peak flow rate < 15 ml/s. Our study presents some correlations with Garraway's experience, making use of clinical and morphological evaluations. A correct clinical and social interpretation of the disease will be feasible only by comparing populations with similar diagnostic and therapeutical patterns.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.